ABSTRACT

The aim of this study was to develop solid dispersion self emulsification pellets (SDSEP). This is a recent technique for poorly water soluble drugs, where it increases water solubility and enhances the bioavailability. A 3² full factorial design approach was used for the optimization of MCC: Lactose (X1) and % of croscarmellose sodium (X2) as variables. Cumulative % drug release (Y1), Disintegration Time (Y2) and Friability (Y3) were studied as response variables. The differential scanning calorimetry and x-ray diffraction studies demonstrated that enhanced dissolution of Ibuprofen from SDSEP might be due to a decrease in the crystallinity of IBU. In conclusion, dissolution enhancement of Ibuprofen was obtained by preparing a Solid Dispersion Self Emulsion using melt technique. The use of a factorial design approach helped in identifying the critical factors in the formulation and formulation of SDSE.

Keywords: Solid Dispersion, Self emulsification, Extrusion spheronization, response variables etc.

1. INTRODUCTION

The improvement of oral bioavailability of poorly water soluble drugs remains one of the most challenging aspects of formulation development. Amidon et al. defined ‘low solubility /high permeability class’, dissolution in the environmental lumen as the rate-controlling step in the absorption process¹. To enhance the oral bioavailability of lipophilic drugs in order to increase their clinical efficacy, the most popular approach would be the incorporation of the active lipophilic component into lipid vehicle², oils³, Salt Formation, Cyclodextrin complexation, Solid dispersion⁴-⁶ self emulsifying formulation⁵-⁹ Micronization, Liposomes¹⁰, Permeation enhancers, lipid solution and microemulsion¹¹-¹⁵. Of this Solid dispersion self emulsification technique can be used to increase the solubility and bioavailability.

Solid dispersion self emulsifying Pellets were formulated as a lipid carrier in which the drug is solubilized and then blended with spheroflux agent as Microcrystalline Cellulose and Lactose. From this system drug releases by self emulsification mechanism when it comes in contact with the gastric fluid and the gentle agitation due to the natural peristaltic movement of the GIT¹⁶-¹⁹.

Experimental design techniques such as factorial design and optimization are useful tools in the characterization of the pharmaceutical processes by studying the effects of variables affecting them and their possible interactions²⁰.

The objective of this study was to determine the effects of the % w/w content of Microcrystalline cellulose and Lactose monohydrate and the concentration of super disintegrant as Croscarmellose sodium using a 3² factorial design.

2. MATERIALS

Ibuprofen (Cipla Pvt Ltd Mumbai), Cithrol GMS 0402 (Croda Chemicals, Singapore) Tween 80, Microcrystalline Cellulose PH101, Lactose Anhydride Granule and Croscarmellose Sodium.

3. METHOD

3.1 Experimental Design

In experimental design we used full factorial 3² method for the optimization procedure. Factors studied were (independent variables) MCC: Lactose monohydrate (X1) and concentration of superdisintegrant (X2). The dependent variables were drug release studied at pH 6.8 buffer (Y1), Disintegration time of pellets (Y2) and Friability rate (Y3).

Table 1 summarizes the independent and dependent variables. Tables 2 shows resulted formulation. Table 3 Optimization parameters for pellet formation.

### Table 1: Experimental design: factors and response

<table>
<thead>
<tr>
<th>Factors (independent variables)</th>
<th>Levels used</th>
<th>Response (dependent variables)</th>
</tr>
</thead>
<tbody>
<tr>
<td>X1 = ratio of Microcrystalline Cellulose: Lactose</td>
<td>100:0</td>
<td>75.25</td>
</tr>
<tr>
<td>X2 = % Concentration of Croscarmellose Na</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3.2 Preparation of Self Emulsifying System

First melted Cithrol GMS, added Tween 80 and made a homogenous mixture. Added Ibuprofen step by step to be completely solubilized in the mixture. Added water into the mixture, with continuous stirring and then cooled to room temperature, to form a milky white cream paste²¹.
Table 2: Composition of experimental formulation

<table>
<thead>
<tr>
<th>Standard Run</th>
<th>Factor-1 MCC: Lactose</th>
<th>Factor-2 Croscarmellose Na</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>-1</td>
<td>-1</td>
</tr>
<tr>
<td>F2</td>
<td>1</td>
<td>-1</td>
</tr>
<tr>
<td>F3</td>
<td>-1</td>
<td>1</td>
</tr>
<tr>
<td>F4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>F5</td>
<td>-1.41</td>
<td>0.00</td>
</tr>
<tr>
<td>F6</td>
<td>1.41</td>
<td>0.00</td>
</tr>
<tr>
<td>F7</td>
<td>0.00</td>
<td>-1.41</td>
</tr>
<tr>
<td>F8</td>
<td>0.00</td>
<td>1.41</td>
</tr>
<tr>
<td>F9</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>F10</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>F11</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>F12</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>F13</td>
<td>0.00</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Table 3: Optimization parameters for pellet formation

<table>
<thead>
<tr>
<th>Process Parameter</th>
<th>Speronization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water concentration (ml)</td>
<td>25-50</td>
</tr>
<tr>
<td>Speronization speed (rpm)</td>
<td>450-930</td>
</tr>
<tr>
<td>Speronization time (min)</td>
<td>5-10</td>
</tr>
<tr>
<td>Drying temperature (°C)</td>
<td>40-45</td>
</tr>
</tbody>
</table>

3.3 Extrusion and Speronization Process:
This cream paste was homogeneously blended with Microcrystalline cellulose, lactose anhydride and croscarmellose sodium. Added sufficient quantity of water to make a dough for extrusion and speronization\(^{21}\).

3.4 Solubility Studies

3.4.1 Microscopy
Solubilized of ibuprofen in Cithrol, Tween 80 was added to water to produce a cream. Ibuprofen at concentrations of 16%, 25%, 33.33% and 50% in the mixture were examined under a compound microscope with 10X objective lens for the presence of ibuprofen crystals and photographs were taken with a resolution digital camera. Solubility studies of ibuprofen in the matrix was measured by microscopy, as reported by Gbolahan Samuel Oladiran\(^{22}\).

3.4.2 Differential Scanning Calorimetry (DSC):
Physical state of the drug in lipid carrier was analyze by DSC studies. Thermal analysis of ibuprofen, the physical mixture of ibuprofen and Lipid carrier, and the solid dispersions were carried out using differential scanning calorimetry method. Sample were examined using a Shimadzu TGA-50DSC instrument (Shimadzu Corporation, Japan). Sample equivalent to approximately 8mg ibuprofen were placed in aluminum pans and heated from 25 to 200°C at heating rate of 10°C/min.

3.4.3 X-ray diffraction studies
X-ray diffraction studies analyze the crystalline nature of the drug in the mixture. X-ray diffraction was performed using a Philips PW 1830 diffractometer (Philips, Netherland), with a monochromatics Cu Kα radiation (λ = 1.54056), having voltage of 50KV, current of 100mA at an angle of 2θ over a range of 5°-40°. Diffraction patterns of pure ibuprofen, Lipid carrier and solid dispersion were prepared at the drug-to-lipid ratio of 1:3 and 1:4 for the determination.

3.5 Assessment of self emulsification: The self emulsifying properties were tested by preparing different pellets containing oil soluble dye without the drug. 1g pellets were added to 50 ml of distilled water and gently agitated for 30min. 1-2 drops of this solution was examined under light microscope\(^{21}\).

3.6 Pellets Analysis

3.6.1 Pellets size: Particle size analysis was performed using a set of sieves in increasing order placed vertically. 100g pellets of the were place on the top sieve and agitated on a sieve shaker for 20 min.

3.6.2 Scanning Electron Microscopy
The shape and surface characteristics of Pellets were observed by a scanning electron microscope (JEOL JSM-840A). The samples were dusted onto double sided tape on an aluminum stub and sputter-coated with gold particles in an argon atmosphere.

3.6.3 3.6.3 Friability: Friability testing was done using friability tester. 10g pellet sample was placed in the drum and rotated for 10 min at 25 rpm.

3.6.4 Disintegration testing of pellets: Modified disintegration tester testing 10 pellets were done using distilled water as the medium at 37°C, and the end point was taken as the point at which no particle were present on the sieve.

3.6.5 In-vitro Drug Release Studies: The in vitro dissolution testing was done using USP method II (paddle method) in 900ml of pH 6.8 phosphate buffer, at 37° C and 70 rpm. Accurately weighted pellets containing the equivalent of 50mg of Ibuprofen were transferred to the dissolution medium. At predetermined intervals of 5, 10, 15, 30, 60 and 120 min., the samples were withdrawn for UV spectrophotometer at a λmax of 221nm.

4 RESULTS AND DISCUSSION

4.1 Microscopic Solubility Studies:
The lipid carrier smear showed no needle shaped crystal as seen in Fig1 A. The smear of 16% and 25% showed no needle shaped crystals as shown in fig 1 (B and C). It indicated total solubilisation of ibuprofen in the lipid carrier. The increasing drug concentration above 33.33% showed needle shaped crystals as seen in the smear as shown in Fig.1 D and E. The results obtained from the microscopic solubility test indicates that by increasing the
Ibuprofen concentration in the carrier above 33.33% needle shaped crystal were seen.

4.2 DSC studies of Lipid Carrier with Ibuprofen:

Thermal Analysis of Lipid carrier, a mixture of Cithrol, Tween 80 and Water is shown in fig.2 A. Physical mixture of Ibuprofen and Lipid carrier is shown in fig. 2 B and Ibuprofen-to-lipid carrier composition ratio (w/w) of 1:1, 1:2, 1:3 and 1:4 were carried out using DSC method as shows in Fig 2 (C to F). Fig 2 A shows DSC results of the lipid carrier with endothermic peak at 56.2°C. The physical mixture of Ibuprofen and lipid carrier at the ratio of 1:1 showed an endothermic peak for ibuprofen at 75.4°C and Carrier peak at 56.4°C, which indicated that ibuprofen was still present in crystalline state. On the other hand, as the amount of Lipid carrier were increased, the endothermic peak of ibuprofen disappeared gradually. At the ratio of 1:2 and above, the DSC curve without endothermic peak of ibuprofen indicate the absence of crystalline ibuprofen and the formation of a solid dispersions. However, an X-ray diffraction study would be needed to confirm this.

4.3 X-rays Studies of carrier and Ibuprofen

X rays powder diffractometry studies for the pure Lipid Carrier (Cithrol+Tween 80+Water), Ibuprofen, Solid Dispersion (1:3) and (1:4) are depicted in fig 3 (A to D) respectively. Pure Ibuprofen gave a diffraction peak corresponding to a separate crystalline drug phag. Solid Dispersion prepared by fusion method showed less intensity of diffraction peak of Ibuprofen pointing to a transition of Ibuprofen from a crystalline to an amorphous state as a consequence of the preparation procedure.

The Microscopic, DSC and X-ray results confirmed that Ibuprofen is present in an amorphous state in the lipid carrier as solid dispersion.

4.4 Assessment of Self emulsification:

The successively self emulsification was evaluated with increasing time and compared with one without a surfactant as it shows in Fig 4 (B to E). In non surfactant batch no oil droplets were seen as show in Fig 4 A and with increasing time increasing oil droplets were seen surfactant in the batches.

4.5 Statistical Design

3² factorial designs were selected for the final optimization of the formulation. 13 experiments were required for the complete design shown in table 4. Formulations were prepared by the varying composition of the two variables viz. quantity of Microcrystalline cellulose: Lactose monohydrate and quantity of percentage of croscarmellose sodium at three different levels i.e. high, medium and low responses (cumulative drug release within 30 min, disintegration time and friability) were measured after each run and the mathematical polynomial equation for the measured response were obtained with statistical package Design expert® version 6 software The polynomial equation relating the responses Y1,Y2 and Y3 and variable was:

Cumulative drug release within 30 min (Y1) = +92.77 -4.00 * A +9.19 * B -0.33 * A * -4.00 * A² -14.07 * B²
Disintegration time (Y2) = +7.40 +1.71 *A -10.42*B +0.50*A*B +2.11 * A² +8.36 * B²
Friability (Y3) = +0.58 -0.34 * A +7.32 E-003 * B +0.000 * A * B +0.091 * A² +0.12 * B²

where A= ratio of Microcrystalline cellulose: Lactose monohydrate and B= Percentage croscarmellose sodium.

<table>
<thead>
<tr>
<th>Normal Run</th>
<th>Standard Run</th>
<th>Response Y1 Cumulative % Drug release within 30 min</th>
<th>Response Y2 Disintegration time (min)</th>
<th>Response Y3 Friability %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F 13</td>
<td>56.42</td>
<td>32</td>
<td>0.3</td>
</tr>
<tr>
<td>2</td>
<td>F 2</td>
<td>62.79</td>
<td>35</td>
<td>1.2</td>
</tr>
<tr>
<td>3</td>
<td>F 8</td>
<td>75.72</td>
<td>7</td>
<td>0.5</td>
</tr>
<tr>
<td>4</td>
<td>F 5</td>
<td>83.41</td>
<td>12</td>
<td>1.3</td>
</tr>
<tr>
<td>5</td>
<td>F 1</td>
<td>83.56</td>
<td>6</td>
<td>0.4</td>
</tr>
<tr>
<td>6</td>
<td>F 7</td>
<td>96.25</td>
<td>10</td>
<td>1.1</td>
</tr>
<tr>
<td>7</td>
<td>F 4</td>
<td>57.89</td>
<td>33</td>
<td>0.8</td>
</tr>
<tr>
<td>8</td>
<td>F 11</td>
<td>81.65</td>
<td>8</td>
<td>0.7</td>
</tr>
<tr>
<td>9</td>
<td>F 10</td>
<td>92.42</td>
<td>7</td>
<td>0.6</td>
</tr>
<tr>
<td>10</td>
<td>F 3</td>
<td>91.88</td>
<td>8</td>
<td>0.6</td>
</tr>
<tr>
<td>11</td>
<td>F 6</td>
<td>93.58</td>
<td>7</td>
<td>0.5</td>
</tr>
<tr>
<td>12</td>
<td>F 9</td>
<td>92.84</td>
<td>7</td>
<td>0.6</td>
</tr>
<tr>
<td>13</td>
<td>F12</td>
<td>93.15</td>
<td>8</td>
<td>0.6</td>
</tr>
</tbody>
</table>
Table 5: One solution found from numerical Optimization

<table>
<thead>
<tr>
<th>Number</th>
<th>MCC:Lactose</th>
<th>Croscarmellose Na</th>
<th>Cumulative % Drug release within 30 min</th>
<th>Disintegration Time</th>
<th>Friability</th>
<th>Desirability</th>
</tr>
</thead>
<tbody>
<tr>
<td>F14</td>
<td>-0.72</td>
<td>0.17</td>
<td>88.9124</td>
<td>5.64543</td>
<td>0.400658</td>
<td>0.861</td>
</tr>
</tbody>
</table>

Table 6: Quantity of excipient used in SDSEP and their predicted and observed response.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Quantity (mg)</th>
<th>Expected</th>
<th>Observed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Cumulative % drug release with in 30 min</td>
<td>Disintegraton time (min)</td>
</tr>
<tr>
<td>A-MCC: Lactose</td>
<td>93.75:6.25 (312:20)</td>
<td>88.92</td>
<td>5.6</td>
</tr>
<tr>
<td>B-Croscarmellose Na</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1: Microscopic solubility studies
Figure 2: DSC Studies of Ibuprofen and Lipid carrier

A: DSC scan of Lipid Carrier

B: DSC scan of Physical Mixture of Ibuprofen and lipid carrier (1:1)

C: DSC scan of Mixture of Ibuprofen: Lipid carrier (1:1)
D: DSC scan of Mixture of Ibuprofen: Lipid carrier (1:2)

E: DSC scan of Mixture of Ibuprofen: Lipid Carrier (1:3)

F: DSC scan of Mixture of Ibuprofen: Lipid Carrier (1:4)
Figure 3: X rays Diffractometry Studies of Ibuprofen and Lipid at 1:3 and 1:4 ratio

A: X ray diffractometry of Lipid Carrier

B: X ray diffractometry Scan of Ibuprofen

C: X ray Diffractometry Scan of Mixture of Ibuprofen: Lipid Carrier (1:3)
D: X ray Diffractometry Scan of Mixture of Ibuprofen: Lipid Carrier (1:4)

Figure 4: Assessment of self emulsification studies

A: Without surfactant
B: 5 min
C: 10 min
D: 15 min
E: 30 min
Figure 5: Response surface plot of cumulative drug release within 30 min.

Figure 6: Response surface plot of disintegration time.

Figure 7: Response surface plot of Friability rate.
Figure 8: Pellets size analysis

Sieve Analysis

Figure 9: Cumulative percent drug release within 30 min

Cumulative Percent Ibuprofen Release

Available online at www.globalresearchonline.net
The above equations represent the quantitative effect of process variables (A, B) and their interaction on the responses (Y1, Y2, Y3). The values of the coefficient A and B are related to the effect of these variables on the responses Y1, Y2 and Y3. Coefficient with more than one factor term and those with higher order terms represent interaction term.

Cumulative percent drug release within 30 min of various batches was in the range of 56.42 to 96.25 as shown in fig 5. The cumulative percent drug release within 30 min of ibuprofen was governed mainly by the % of croscarmellose sodium. It was found that as the concentration of croscarmellose sodium increased, there was an increase in the cumulative drug release within 30 min. Croscarmellose sodium was used as super disintegrant, increasing disintegration and cumulative drug release within 30 min. The second factor MCC: Lactose had less effect on cumulative drug release. Lactose concentration was increased showing increase in cumulative drug release within 30 min. These results are comparable to the results obtained by Blanche et al., 1995, who found that the high solubility of lactose provides a faster drug release23.

Disintegration time of the various batches was in the range of 5 to 35 min as shown in fig 6. Disintegration time of pellets was governed mainly by % of croscarmellose sodium. It was found that as the concentration of croscarmellose sodium increases, there was a decrease in disintegration time. Croscarmellose sodium was used as super disintegrant, it increases disintegration of pellets and decrease disintegration time. The other factor MCC: Lactose showed less effect on disintegration time. Lactose concentration increases disintegration time.

This result is similar with Blanche et al, who reported that highly porous pellets were formed during disintegration and dissolution24.

Friability of the various batches was in the range of 0.3 to 1.3 as shown in fig 7. Friability of pellets were governed mainly by the rate of MCC: Lactose. It was found that as the concentration of lactose increased in the ratio of MCC: Lactose, there was an increase in friability and vice versa. But high concentration of MCC decreased friability of pellets and decrease drug release. Therefore the optimum concentration of lactose was required to get less friability and optimum drug release. The other factor namely % of Croscarmellose sodium had less effect on friability. This result is similar to the results obtained by Sousa et al., 2002 who found that the higher the proportion of MCC in the pellets, the greater was the mechanical strength of the pellets23. The other factor namely % Croscarmellose sodium had less effect on friability.

Statistical optimization

The experimental runs with the predicted solution are shown in Table No 5. Formulated the solution Batch F14 as shown in Table no 5, then observed the results and compared the results with the predicated results as shown in table no 6 This demonstrates the reliability of the optimization procedure in predicting the Cumulative percent drug release within 30 min, Disintegration time (min) and Friability (%).  

4.6 Pellets Size analysis: Sieve analysis was done and its value of geometric mean diameter (d4) was 1mm. All batches showed pellets size in the optimized range of 800µm to 1000µm as shown in fig 8.

4.7 In-vitro Drug Release Studies:

In vitro dissolution tests of F14 showed 92.42 % drug release within 30 min (fig 9). Ibuprofen release was optimized from different ratios of MCC; Lactose monohydrate and croscarmellose sodium.

CONCLUSION

The immediate release of water insoluble Ibuprofen from pellet formulation was possible by incorporating them into a Solid Dispersion Self Emulsifying system with croscarmellose Na, which enhanced their rate of release. Increasing Lactose % showed fast release but friability increased and high MCC level was required to achieve low level of friability. 1% Croscarmellose Na was sufficient to get 92.72% drug release within 30 min.

The SEDDS pellets were successfully characterized for its physical parameters such as size analysis, friability, disintegration and invitro dissolution.

Acknowledgement: The authors are grateful to Cipla Pharmaceutical Pvt.Ltd. and Croda Chemicals Mumbai for providing gift sample of Ibuprofen and Cithrol GMS 402 respectively.

REFERENCES


5. Aungest BJ, Nguyen N, Rogers NJ, Rowe S, Hussain M, Shum L, White S, Improved oral bioavailability of an


